Oncology has always been one of the hottest research areas in pharma. As of August 2018, 40% of the 3500 new molecular entities (NMEs) in development were oncology products. Applying probability of success benchmarks to the current pipeline indicates 600 of these 1,400 new drugs will reach the market. But of these 600, how many will offer meaningful benefits to patients rather than incremental improvements measured in months and often paired with side effects? Panelists will address this concern as well as address other pressing questions, such as how will these new drugs be paid for, especially amidst increasing pricing and payer pressure?

Ability Level: All

Session ID: 503563